This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (30)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Neoplasms  • Gastroenterology  • Liver/ Biliary Tract/ Pancreatic Diseases  • Genetics  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Jana Foley Parker, MD; Scott R. Florell, MD; April Alexander, MD; James A. DiSario, MD; Paul J. Shami, MD; Sancy A. Leachman, MD, PhD

Arch Dermatol. 2003;139:1019-1025.

Objective  To determine the optimal methods for pancreatic adenocarcinoma surveillance in high-risk patients with familial melanoma and cyclin-dependent kinase inhibitor 2A (CDKN2A) mutations.

Design  Case report with pedigree analysis and literature review, with an emphasis on guideline development for high-risk kindreds with familial pancreatic adenocarcinoma.

Setting  A university-affiliated familial melanoma research clinic.

Patients  The proband was referred as a participant in a research clinic protocol and was found to carry a germline CDKN2A mutation and have a history of melanoma and pancreatic adenocarcinoma. A total of 179 family members were identified through the Utah Population Database and underwent evaluation for history of melanoma and pancreatic adenocarcinoma.

Intervention/Methods  Comprehensive family history and pedigree analysis performed by means of personal interview, medical record review, and use of cancer registry and population database records. Mutation status was confirmed by results of DNA sequence analysis. Tumor identity was confirmed with immunohistochemical markers.

Main Outcome Measures  Estimated risk for pancreatic adenocarcinoma in a high-risk family with CDKN2A-positive melanoma. Guidelines for surveillance in these families were based on review of the literature.

Results  Sequence analysis confirmed a CDKN2A mutation, and immunohistochemical evaluation confirmed the diagnoses of metastatic melanoma and metastatic pancreatic adenocarcinoma. Pedigree analysis showed an observed-expected ratio of 8.9 to 12.6 for pancreatic adenocarcinoma and 16.4 to 20.8 for melanoma in this family. Guidelines used for surveillance of kindreds at high risk for pancreatic adenocarcinoma were applied to families with CDKN2A melanoma.

Conclusion  Patients with melanoma and a germline CDKN2A mutation should be considered for pancreatic adenocarcinoma surveillance that is based on the most recent published studies.

From the Department of Dermatology and Huntsman Cancer Institute (Drs Florell, Alexander, and Leachman) and the Divisions of Gastroenterology (Dr DiSario) and Oncology (Dr Shami), Department of Internal Medicine, University of Utah (Dr Parker), and the Division of Oncology, Department of Internal Medicine, Salt Lake City Veterans Affairs Medical Center (Dr Shami), Salt Lake City, Utah. The authors have no relevant financial interest in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Screening for Pancreatic Cancer in High-Risk Individuals: A Call for Endoscopic Ultrasound
Larghi et al.
Clin. Cancer Res. 2009;15:1907-1914.
ABSTRACT | FULL TEXT  

Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents
Goldstein et al.
J. Med. Genet. 2007;44:99-106.
ABSTRACT | FULL TEXT  

High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL.
Goldstein et al.
Cancer Res. 2006;66:9818-9828.
ABSTRACT | FULL TEXT  

Population-Based Analysis of Prognostic Factors and Survival in Familial Melanoma
Florell et al.
JCO 2005;23:7168-7177.
ABSTRACT | FULL TEXT